ANTI-vascular endothelial growth factor therapy for proliferative diabetic retinopathy

Retina

Volumn 35, Issue 10, 2015, Pages 1931-1942

  Simunovic, Matthew P ^a,b,c   Maberley, David A L ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD EYE HOSPITAL   (United Kingdom)

^c MOORFIELDS EYE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Bevacizumab; Diabetic retinopathy; Diabetic vitrectomy; Diabetic vitreous hemorrhage; Pegaptanib; Proliferative diabetic retinopathy; Ranibizumab

Indexed keywords

BEVACIZUMAB; CONNECTIVE TISSUE GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PEGAPTANIB; RANIBIZUMAB; SILICONE OIL; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

CENTRAL MACULAR THICKNESS; CENTRAL RETINAL THICKNESS; CONTRAST SENSITIVITY; DIATHERMY; ENDOPHTHALMITIS; HUMAN; LASER COAGULATION; META ANALYSIS; OUTCOME ASSESSMENT; PROLIFERATIVE DIABETIC RETINOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS HEMORRHAGE; ANTAGONISTS AND INHIBITORS; DIABETIC RETINOPATHY; INTRAVITREAL DRUG ADMINISTRATION;

ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; HUMANS; INTRAVITREAL INJECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84942411845     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000723     Document Type: Review

References (42)

1. WHO. Prevention of Blindness from Diabetes Mellitus. Geneva, Switzerland: World Health Organization; 2005.
2. Lebherz C, Maguire AM, Auricchio A, et al. Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor. Diabetes 2005;54:1141-1149.
3. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
4. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: sixmonth primary end point results of a phase III study. Ophthalmology 2010;117:1102-1112 e1101.
5. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117:1078-1086 e1072.
6. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-625.
7. Ip MS, Domalpally A, Hopkins JJ, et al. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 2012;130:1145-1152.
8. Moradian S, Ahmadieh H, Malihi M, et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2008;246:1699-1705.
9. Arevalo JF, Maia M, Flynn HW, Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:213-216.
10. Lee SJ, Koh HJ. Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (avastin) with pars plana vitrectomy. J Ocul Pharmacol Ther 2009;25:173-174.
11. Verhagen AP, de Vet HC, de Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998;51:1235-1241.
12. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-926.
13. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383-394.
14. The U.S. Preventive Services Task Force. Available at: http://www.uspreventiveservicestaskforce.org/. Accessed April 2015.
15. Rev Man. Version 5.1. Copenhagen, Denmark: The Cochrane Collaboration; 2011.
16. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane collaboration; 2011. Available from www.cochrane-handbook.org.
17. Lucena D da R, Ribeiro JA, Costa RA, et al. Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol 2009;93:688-691.
18. Preti RC, Ramirez LM, Monteiro ML, et al. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial. Br J Ophthalmol 2013;97:885-889.
19. Maturi RK, Plous OZ, Diaz-Rohena R, et al. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol 2013;131:283-293.
20. Gonzalez VH, Giuliari GP, Banda RM, Guel DA. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. Br J Ophthalmol 2009;93:1474-1478.
21. Ernst BJ, Garcia-Aguirre G, Oliver SC, et al. Intravitreal bevacizumab versus panretinal photocoagulation for treatmentnaive proliferative and severe nonproliferative diabetic retinopathy. Acta Ophthalmol 2012;90:e573-e574.
22. Filho JA, Messias A, Almeida FP, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol 2011;89:e567-e572.
23. Messias A, Ramos Filho JA, Messias K, et al. Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy. Doc Ophthalmol 2012;124:225-236.
24. Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011;31:1009-1027.
25. Cho WB, Oh SB, Moon JW, Kim HC. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 2009;29:516-522.
26. Mirshahi A, Roohipoor R, Lashay A, et al. Bevacizumabaugmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 2008;18:263-269.
27. Tonello M, Costa RA, Almeida FP, et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008;86:385-389.
28. Preti RC, Vasquez Ramirez LM, Ribeiro Monteiro ML, et al. Structural and functional assessment of macula in patients with high-risk proliferative diabetic retinopathy submitted to panretinal photocoagulation and associated intravitreal bevacizumab injections: a comparative, randomised, controlled trial. Ophthalmologica 2013;230:1-8.
29. Rizzo S, Genovesi-Ebert F, Di Bartolo E, et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008;246:837-842.
30. Modarres M, Nazari H, Falavarjani KG, et al. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2009;19:848-852.
31. Farahvash MS, Majidi AR, Roohipoor R, Ghassemi F. Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage. Retina 2011;31:1254-1260.
32. Hernandez-Da Mota SE, Nunez-Solorio SM. Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy. Eur J Ophthalmol 2010;20:1047-1052.
33. di Lauro R, De Ruggiero P, di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010;248:785-791.
34. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology 2009;116:1943-1948.
35. Ahn J, Woo SJ, Chung H, Park KH. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology 2011;118:2218-2226.
36. Sohn EH, He S, Kim LA, et al. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1. Arch Ophthalmol 2012;130:1127-1134.
37. Han XX, Guo CM, Li Y, Hui YN. Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1alpha. Mol Vis 2012;18:1-9.
38. El-Batarny AM. Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy. Clin Ophthalmol 2008;2: 709-716.
39. Zhang ZH, Liu HY, Hernandez-Da Mota SE, et al. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials. Am J Ophthalmol 2013;156:106-115 e102.
40. Moisseiev E, Waisbourd M, Ben-Artsi E, et al. Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes. Graefes Arch Clin Exp Ophthalmol 2014; 252:331-337.
41. Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 2012;154:682-686 e682.
42. Osaadon P, Fagan XJ, Lifshitz T, Levy J. A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye (Lond) 2014;28:510-520.